Ongoing Clinical Trials for Adenosquamous Cell Lung Cancer Stage I
There is currently 1 ongoing clinical trial investigating new diagnostic approaches for adenosquamous cell lung cancer stage I. This trial is testing a breath-based test that could help identify lung cancer more accurately in patients eligible for screening or those with suspicious CT scan findings. The trial is being conducted in Hungary and Czechia.
Clinical trial locations
- Czechia
- Hungary
Study on the Accuracy of OWL-EVO1 Test for Diagnosing Lung Cancer in Patients Eligible for Screening or with Suspicious CT Findings
This trial is investigating a new diagnostic test called the OWL-EVO1 Breath Biopsy test, which aims to help doctors determine whether a patient has lung cancer or not. The test works by analyzing breath samples to detect specific markers that may indicate the presence of cancer. This non-invasive approach could potentially provide earlier and more accurate detection of the disease compared to traditional methods.
Who can participate: The trial is open to adults between 45 and 85 years of age who are able to understand the study and provide informed consent. Participants must have a Body Mass Index between 16 and less than 40, and must have had a CT scan of the chest area within the last 6 months. This makes the trial suitable for people who are either eligible for lung cancer screening or who have findings on their CT scan that might suggest the presence of cancer.
Who cannot participate: The trial excludes individuals who are not eligible for lung cancer screening based on low dose CT scans. It also excludes those who do not have any suspicious findings on their CT scan that could indicate lung cancer, as well as people whose symptoms do not suggest lung cancer as a possible diagnosis.
What the trial involves: After joining the study and confirming eligibility, participants will receive an intravenous infusion of a solution called D5-ethyl-beta-D-glucuronide, which helps in the testing process. Breath samples will then be collected at various timepoints to evaluate how well the OWL-EVO1 test can identify lung cancer. Throughout the study, participants will be monitored for any side effects or adverse reactions to ensure the test is safe and well-tolerated.
Investigational approach: The OWL-EVO1 test is a diagnostic tool that analyzes volatile organic compounds in the breath. These compounds can serve as biomarkers that indicate the presence of cancer cells in the lungs. The goal is to determine whether this breath-based test can reliably differentiate between people with lung cancer and those with other conditions that might produce similar findings on imaging scans.
Summary
Currently, there is one clinical trial available for patients with adenosquamous cell lung cancer stage I. This trial is being conducted in two European countries: Czechia and Hungary. The focus of this research is on improving diagnostic accuracy through a novel breath-based test, rather than testing new treatments. This reflects an important area of cancer research, as early and accurate detection of lung cancer can significantly impact patient outcomes. The OWL-EVO1 test represents a potentially less invasive alternative to traditional diagnostic procedures, which could make screening more accessible and comfortable for patients. The trial is expected to conclude in late 2024, at which point the findings will help determine whether this diagnostic approach can be used more widely in clinical practice.
